A Phase 2 interventional study of Full Dose Strength and Quarter dose strength in Dental Pain, sponsored by AFT Pharmaceuticals, Ltd.. Withdrawn at 1 site in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-07-12.
Sponsored by AFT Pharmaceuticals, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Toothache with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Toothache · United States.
Among the 55 studies in Toothache with a site in United States, this one is the 50th largest by enrollment of the 51 interventional ones that give a count, is one of 21 in phase 2, and was the 18th registered.
142 studies on the registry are indexed under Toothache; 28 are open to participants now.
Browse Toothache studies →7 of the 55 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:
Cytogel Pharma, LLC · Sites in United States
Ages 18–45 · Healthy volunteers
University of Florida · Sites in United States
Ages 18+ · Healthy volunteers
University of Maryland, Baltimore · Sites in United States
Ages 6–12 · Healthy volunteers
Cleveland Dental Institute · Sites in United States
Ages 20–60
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 16 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 23 · Phase 3 11 · Phase 4 10
First in 2004; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 193 across the 51 interventional studies, 82 across the 4 observational. Of the 45 that completed or were terminated, 30 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 55 have an industry lead sponsor. The 10 most frequent:
AFT Pharmaceuticals, Ltd. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
AFT Pharmaceuticals, Ltd. has 2 studies filed under Toothache — fewer than ten, so there is no comparison to draw.
5 of the studies in Toothache with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04860141Loma Linda UniversityEfficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction. | 2026-12 |
| NCT06330207University of FloridaAn Emergency Department (ED) Provider Centered Intervention for Non-Traumatic Dental Condition Management (NTDC) | 2027-02-01 |
| NCT07945431South Rampart Pharma, Inc.A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction | 2027-02-28 |
| NCT06691269University of Maryland, BaltimorePhotobiomodulation and Tooth Analgesia | 2027-06 |
| NCT07905105Cytogel Pharma, LLCA Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies in Toothache with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to examine the dose response relationship in the treatment of dental pain (teeth extraction) for the different potential doses of the investigational drug, i.e. 2 tablets, 1 tablet or ½ a tablet given 4 times a day.
The combination of 500 mg acetaminophen and 150 mg ibuprofen has been shown to improve analgesia compared with the individual components, when given as 2 tablets (i.e., total of 1,000/300 mg) 4 times a day for dental pain.
The analgesic relief from 2 tablets of the combination was around 6 hours, and so consistent with 4 times a day dosing.
The combination tablets are scored to allow for lower doses and can be given as 2 tablets (total of 1,000/300 mg), 1 tablet (500/150 mg) or ½ tablet (250/75 mg) in multiple doses.
However different dose response combinations need to be investigated to confirm the dose response curve of the combination and to compare the relative efficacy with acetaminophen and different doses of ibuprofen (lower and higher dose).
The study hypothesis is the analgesic response to three different combination doses, the three single component doses 500mg acetaminophen and 150mg and 300mg ibuprofen, and placebo administered four times daily over 24 hours for post-operative dental pain will form a representative dose response curve.
The study design is multi-centre, prospective, placebo-controlled, randomized, double-blind, factorial parallel group.
Participants will be stratified for baseline pain at inclusion (moderate or severe pain based a 4 point pain intensity rating scale).
Recruitment will continue until there are at least 350 participants in the ITT population.
Efficacy: The primary efficacy objective is to compare the time-adjusted SPIDs (Summed Pain Intensity Differences) of the VAS pain intensity scores up to 24 hours after the first dose of study medication among the 7 treatment groups to determine the form of the dose-response relationship.
Secondary efficacy objectives are:
Safety:
To compare adverse event rates (divided into serious and non-serious adverse events). Adverse events will be assessed for the 24- hour study period and up to 30 days after the final dose of study medication among the seven treatment groups.
The standard symptoms expected in subjects who have recently undergone third molar extraction will not be recorded as AEs in this study, unless they are of greater severity and/or intensity than would be expected. The events considered to be standard for the purposes of this study are:
The Investigators will use their clinical judgement in determining whether these symptoms are of greater severity and/or intensity than would be expected.
Planned hospital admissions and/or surgical operations for an illness or disease which existed before the drug was given or the participant was randomized in a clinical study will not be considered adverse events The incidence of known specific NSAID and acetaminophen side effects (e.g. GI ulceration, Indigestion/stomach pain, post-operative bleeding, thromboembolic events and evidence of clinical hepatitis) during the 24-hour study period and up to 30 days after the last dose will be compared among the seven treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Study :
Participant weight \< 50kg.Suffering from any other diseases or condition which, in the opinion of the investigator, means that it would not be in the participant's best interests to participate in this study.
NSAID and/or acetaminophen contra-indications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg), i.e 2 tablets equating to ½ the dose in the standard investigational drug
Drug: Half dose strength
Investigational drug quarter dose strength (acetaminophen125mg + Ibuprofen 37.5mg) i.e. 2 tablets equating to ¼ the dose in the standard investigational drug.
Drug: Quarter dose strength
Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
Drug: Acetaminophen standard dose
Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
Drug: Ibuprofen low dose
Ibuprofen High dose 300mg i.e. 2 tablets equating to twice the ibuprofen dose as in the standard investigational drug
Drug: Ibuprofen high dose
2 Placebo tablets
Drug: Placebo
Investigational drug full dose strength (acetaminophen 500mg + ibuprofen 150mg) i.e. 2 tablets
Drug: Full Dose Strength
Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
Also known as: Brand name Maxigesic
Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
Also known as: Maxigesic Quarter Dose
Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
Also known as: Maxigesic half dose
Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
Also known as: paracetamol
Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
Also known as: Ibuprofen
Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
Also known as: Ibuprofen
2 placebo tablets
the time-adjusted SPIDs of the VAS pain intensity scores
The primary efficacy objective is to compare the time-adjusted SPIDs of the VAS pain intensity scores up to 24 hours after the first dose of study medication among the 7 treatment groups to determine the form of the dose-response relationship.
Time frame: 24 hours after the first dose
the maximum VAS pain score
To compare the maximum VAS pain scores for the 24-hour period after the first dose of study medication among the seven treatment groups to determine the form of the dose response relationship.
Time frame: 24 hours after the first dose
The Response Rate
To compare the response rates (response rate to be defined as the percentage of participants who achieve at least 50% reduction in baseline pain within 6 hours i.e. the first dose period) among the seven treatment groups to determine the form of the dose response relationship.
Time frame: 24 hours after the first dose
The time to peak reduction in VAS pain intensity scores
To determine and compare the time to peak reduction in VAS pain intensity scores following the first dose of study medication among the seven treatment groups to determine the form of the dose response relationship.
Time frame: 24 hours after the first dose
The time to perceptible and meaningful pain relief
To compare time to perceptible and meaningful pain relief among the seven treatment groups using the two stopwatch method.
Time frame: 24 hours after the first dose
The time to requirement for rescue medication
To compare the time to requirement for rescue medication among the seven treatment groups.
Time frame: 24 hours after the first dose
The amount of rescue medication used
To compare the amount of rescue medication used (defined as the number of tablets) among the seven treatment groups over the 24-hour treatment period.
Time frame: 24 hours after the first dose
The percentage of participants requiring rescue medication
To compare the percentage of participants requiring rescue medication among the seven treatment groups.
Time frame: 24 hours after the first dose
The categorical global pain rating
To compare the categorical global pain rating among the seven treatment groups which is obtained at the end of 24 hours study period.
Time frame: 24 hours after the first dose
The incidence of adverse events
Adverse events (divided into serious and non-serious adverse events) will be assessed for the study period. Adverse events will also be determined up to 30 days after the last dose. The incidence of individual specific NSAID and acetaminophen side effects (e.g. GI ulceration, indigestion/stomach pain, post-operative bleeding and evidence of clinical hepatitis) will be determined up to 30 days after the last dose.
Time frame: up to 30 days after the last dose
This study is withdrawn, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen
AFT Pharmaceuticals, Ltd.